NVS241220P145000
- 0.00
- 0.000.00%
Novartis AG Newsroom
Olema in Deal With Novartis on Kisqali Breast Cancer Combo Collaboration
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Sector Update: Health Care
ptc therapeutics (PTCT.US) signed a Huntington's disease drug licensing agreement with novartis ag (NVS.US).
The stock price of ptc therapeutics (PTCT.US) rose 21% in pre-market trading on Monday.
PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones
Press Release: Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement
Novartis AG (NVS): A Bull Case Theory
Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Wedbush Assumes Coverage of Voyager With Outperform Rating
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to transform the treatment of early-stage breast cancer.
Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.
European Commission Approves Products by BeiGene, GSK and Novartis
The European Commission Has Approved Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer At High Risk...
Novartis' Early Breast Cancer Drug Gets Approval From EU Commission
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation
Novartis (NVS.US) has launched hydrochloride acyclovir tablets in the domestic market, indicated for IgA nephropathy.
Acarbose is an investigational high-potency selective oral ETA (endothelin A) receptor antagonist, activation of the ETA receptor results in increased proteinuria, which is associated with kidney damage, fibrosis, and loss of renal function in IgA nephropathy.
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
BMO Capital Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $156
6-K: Novartis Upgrades Mid-Term Guidance